Forte Biosciences (NASDAQ:FBRX) announces full results of Phase 1/2a trial of lead product candidate, FB-401 in atopic dermatitis (AD) patients in Science Translational Medicine.
In the pediatric cohort, 20 AD patients of age from 3 to 16 years of age, were treated topically with FB-401 for 16 weeks.
90% (18/20) of the pediatric patients reported at least a 50% improvement in the Eczema Activity and Severity Index (EASI-50) with 100% (9/9) of the moderate-to-severe patients achieving EASI-50.
The mean improvement in the EASI score was 77% with development observed on all actively treated body sites. Pruritus (itch) also improved by an average 58%.
The mechanism of action for FB-401 involves pathways that drive tissue repair and anti-inflammation.
Overall, FB-401 demonstrated excellent tolerability and significant improvement in disease activity in both adults and children.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.